海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)
- IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Canada, Hungary, Lithuania, Slovakia, Spain, United States
- 2018-04-20
Authorised
- A clinical study investigating the efficacy, tolerability and safety of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with a diagnosis of bipolar I disorder
- Treatment of Manic Episodes Associated with Bipolar I Disorder MedDRA version: 20.0 Level: LLT Classification code 10068455 Term: Bipolar I disorder, hypomanic System Organ Class: 100000004873 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Croatia, Romania, Ukraine, United States
- 2018-04-12
Authorised
- OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)
- IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Canada, Hungary, United States
- 2018-03-29
Authorised
- Study of efficacy and safety of secukinumab 1 mL pre-filled syringe (300 mg) in subjects of body weight 90 kg or higher with moderate to severe plaque psoriasis.
- Moderate to severe chronic plaque-type psoriasis MedDRA version: 20.0 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Hungary, Italy, Russian Federation, United States
- 2018-03-22
Authorised
- A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, China, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Jordan, Korea, Republic of, Latvia, Lebanon, Lithuania, Macedonia, the former Yugoslav Republic of, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom, United States
- 2018-03-01
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-21
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-13
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-02-12
Authorised
- An open-label clinical trial of volanesorsen in patients with Familial Chylomicronemia Syndrome (FCS)
- Familial Chylomicronemia Syndrome (FCS) MedDRA version: 20.0 Level: LLT Classification code 10017339 Term: Fredrickson Type I lipidaemia System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10060593 Term: Fredrickson Type I lipidemia System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Brazil, Canada, France, Germany, Israel, Italy, Netherlands, South Africa, Spain, United Kingdom, United States
- 2016-02-26
Authorised
- Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
- Retinopathy of Prematurity (ROP);Therapeutic area: Body processes [G] - Ocular Physiological Phenomena [G14]
- Italy, Netherlands, Poland, Sweden, United Kingdom, United States
- 2014-12-22